During the past decade, Institut Curie conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 1 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 1 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institut Curie" #1 sponsor was "Eli Lilly and Company" with 3 trials, followed by "Amgen" with 1 trials sponsored, "Centre Leon Berard" with 1 trials sponsored, "Daiichi Sankyo, Inc." with 1 trials sponsored and "Gilead Sciences" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut Curie" #1 collaborator was "Centre de Recherche en Cancérologie de Lyon" with 1 trials as a collaborator, "Innovative Therapies for Children with Cancer in Europe (ITCC)" with 1 trials as a collaborator, "NSABP Foundation Inc" with 1 trials as a collaborator and "New Approaches to Neuroblastoma Therapy Consortium (NANT)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Institut Curie" are "Breast Cancer" (2 trials), "Diffuse Large B-cell Lymphoma" (1 trials), "EGFR Exon 19 Deletion" (1 trials), "EGFR L858R" (1 trials) and "Lymphoma" (1 trials). Many other conditions were trialed in "Institut Curie" in a lesser frequency.

Most popular intervention types in "Institut Curie" are "Drug" (7 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "LY3295668 Erbumine" (2 trials), "Abemaciclib" (1 trials), "Blood sample for genetic analysis (Identification of germ line genetic factors that influence the risk of metastatic breast cancer)" (1 trials), "Cyclophosphamide" (1 trials) and "Docetaxel" (1 trials). Other intervention names were less common.

The vast majority of trials in "Institut Curie" are 7 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Institut Curie". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Institut Curie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Institut Curie, 2 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".